Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2006

View Archived Issues

Medarex looks back on achievements

Cangrelor demonstrates advantages over abciximab in patients undergoing PCI

Mepolizumab decreases eosinophilia in hypereosinophilic syndromes, esophagitis

Novel anti-HGF MAb L2G7 exhibits profound effects in mice bearing intracranial glioma xenografts

Targeted Genetics supports plans for 2006 through new financing

Dusa closes acquisition of Sirius Laboratories

Pharmos to acquire Vela Pharmaceuticals

Enrollment completed in SPIRIT III study of Xience V stent

Roche expands manufacturing network for production of Tamiflu

GenVec expands TNFerade phase II study into phase II/III trial

Edison and university partners establish mitochondrial disease collaboration

AdvaTab Cetirizine completes pharmacokinetic study

Phase II pilot study assesses Oxycyte in traumatic brain injury

Novavax collaborative HIV program receives additional funding

LymphoSign completes preclinical testing of LS-104

V-1003 superior to Vicodin for pain relief

Significant decline in HBV viral load in pradefovir study

Sativex produces improvement in MS-related spasticity

Human Genome Sciences reports new phase II data for Albuferon

ALK5 inhibitor a novel therapeutic approach for the treatment of fibrosis

Recent patents impart new therapeutic agents for cancer

New agents for treating thrombocythemia reported in recent Shire patent

Targeting the M. tuberculosis proteasome for novel tuberculosis therapies

ARRY-649: A novel, highly potent KSP inhibitor from Array BioPharma

The glycolytic enzyme GAPDH as a target for neuroprotection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...